Latest Healthcare News

Careteq Limited has raised $625,000 through a convertible note from investor Antanas Guoga and loans from its board, strengthening its working capital position for the medium term.

Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Botanix Pharmaceuticals has secured a US$30 million debt facility from Kreos Capital, bolstering its financial position to commercialize Sofdra™ and pursue platform expansion opportunities.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

EZZ Life Science has inked a three-year distribution deal with ROFA Enterprises, marking a significant step into Southeast Asia’s booming health market. The agreement guarantees at least A$21 million in sales across Thailand, Vietnam, and Singapore.

Integral Diagnostics has announced the planned retirement of CEO Dr Ian Kadish at the end of FY26, with an international search underway for his successor. The transition comes as the company focuses on integrating its recent merger with Capitol Health.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.